CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 165 enrolled
Drug / intervention
LY2484595 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01375075
NCT01375075Phase 2Completed
CompareCT.gov

A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects

Eli Lilly and Company·interventional·Posted Jun 17, 2011·Updated Oct 25, 2018

In Brief

A Phase 2 clinical trial evaluating LY2484595, Placebo, and 1 other intervention for Dyslipidemias. Completed, enrolled 165 participants across 5 sites.

Detailed Summary

The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2011
Enrollment StartJun 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.0 years ago

Interventions

LY2484595drug

Administered orally

Placebodrug

Administered orally

Atorvastatindrug

Administered orally